Share This Link

N1 does not indicate absence of lymph node involvement; it specifically means there is spread to regional lymph nodes. M0 also means that distant metastasis has not occurred, not that it has occurred. Although T2 may represent a larger tumor than T1, the presence of metastasis stated here does not match the classification.

Localized cancer without lymph node involvement would be classified as N0 rather than N1. T2 also suggests progression beyond the earliest stage and is not simply described as fully localized disease. Since lymph nodes are involved in this case, the description does not accurately reflect the staging provided.

This option is incorrect because carcinoma in situ is usually represented by Tis rather than T2. In addition, M0 means there is no distant metastasis, while this option states that distant spread is present. The description of in situ disease with metastasis is also clinically inconsistent because in situ tumors have not invaded beyond the basement membrane.

Decreasing blood pressure is not the primary purpose of lactulose in hepatic encephalopathy. Lactulose acts mainly within the gastrointestinal tract and does not function as an antihypertensive medication. Although fluid shifts may occur with excessive diarrhea, blood pressure reduction is not its therapeutic target in this condition.

Improving liver function tests is not the direct action of lactulose. The medication does not repair hepatocytes or restore liver enzyme levels such as AST, ALT, or bilirubin. Its benefit is focused on reducing neurotoxic ammonia accumulation rather than reversing the underlying hepatic damage shown in laboratory values.

Increasing sodium levels in the body is not the intended use of lactulose. It does not act as an electrolyte replacement therapy and may actually contribute to electrolyte imbalance if excessive diarrhea occurs. Sodium management in liver disease is addressed separately, especially in clients with ascites or fluid retention.

Administering an anxiolytic may be helpful if anxiety is contributing to hyperventilation, but in this case the client is on mechanical ventilation, making ventilator settings the more direct and immediate cause to address. Priority should be given to correcting the mechanical source of excessive ventilation first. Sedation without adjusting ventilation may delay proper correction of the alkalosis.

Administering sodium bicarbonate is inappropriate because sodium bicarbonate is used to treat metabolic acidosis, not respiratory alkalosis. This client already has an elevated pH of 7.5, indicating alkalemia, and giving bicarbonate would worsen the imbalance. The low PaCO2 confirms that the primary problem is excessive carbon dioxide loss rather than bicarbonate deficiency.

Increasing oxygen concentration is not the priority because the ABG findings indicate a ventilation problem rather than an oxygenation problem. The major abnormality is low PaCO2 caused by excessive respiratory rate, not evidence of hypoxemia. Raising oxygen concentration will not correct respiratory alkalosis and may expose the client to unnecessary oxygen-related complications.

Benign tumors do not spread to distant organs or invade surrounding tissues. They are usually encapsulated, remain confined to their original location, and cause problems mainly by pressure on nearby structures. The ability to invade and metastasize is a defining feature of malignant tumors, not benign growths. Therefore, this statement incorrectly describes benign tumors.

Malignant tumors are not typically well-defined or slow-growing. They often have irregular borders, rapid and uncontrolled cell division, and poorly differentiated cells that do not resemble normal tissue. Localized effects with clear boundaries are more characteristic of benign tumors, making this description inaccurate for malignancy.

Benign tumors are generally less likely to cause severe systemic symptoms than malignant tumors. Malignant tumors commonly produce systemic effects such as weight loss, fatigue, anemia, and cachexia due to aggressive growth and metastasis. Benign tumors usually cause localized symptoms unless they compress vital organs or produce hormones.

Cholecystitis is inflammation of the gallbladder and is not a typical complication directly associated with a TIPS procedure. It is more commonly related to gallstones, infection, or biliary stasis rather than portal venous shunting. While clients with liver disease may have multiple abdominal issues, cholecystitis is not the expected post-TIPS complication being assessed here.

Biliary obstruction is not a common complication of TIPS because the procedure primarily involves vascular structures rather than the biliary tract. Although rare technical complications may affect nearby structures, routine concern after TIPS is not obstruction of bile flow. Monitoring usually focuses more on bleeding, shunt patency, and neurologic changes rather than biliary blockage.

Ascites is often one of the reasons TIPS is performed rather than a complication caused by it. By lowering portal venous pressure, TIPS helps reduce fluid accumulation in the abdomen and is commonly used for refractory ascites management. Persistent or worsening ascites may indicate shunt dysfunction, but ascites itself is not the classic expected complication after the procedure.

Storing nitroglycerin in an open bottle or pill organizer is inappropriate because exposure to air, moisture, and light causes the tablets to lose potency rapidly. The original tightly sealed glass container is specifically designed to protect the medication from environmental degradation. Using pill organizers increases the risk that the client will receive ineffective medication during an angina attack.

Refrigeration is not recommended for routine storage of sublingual nitroglycerin tablets. Extreme temperatures and moisture from refrigeration can negatively affect the medication and compromise tablet stability. The preferred storage method is at room temperature in the original light-resistant container, away from heat, humidity, and direct sunlight.

Nitroglycerin is not routinely discarded after one month regardless of appearance. Most recommendations advise replacing tablets approximately every 6 months after opening, depending on manufacturer guidance and storage conditions. The key concern is loss of potency rather than visible changes, so the medication should be checked based on expiration guidance rather than an arbitrary one-month rule.